Seattle-based Cyrus Biotechnology is entering a protein engineering collaboration with Boston-based Selecta Biosciences that could pull in up to $1.5 billion for the University of Washington spinout. The partnership will support the development of new agents for immune-related conditions, the companies announced this week. The partnership includes an undisclosed up-front payment and is worth up to $1.5 billion for Cyrus…
Read More
Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The seven recipients will receive a combined total of $1 million in grants over a two-year period, making…
Read More
A better understanding of the metabolic alterations in immune cells during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may elucidate the wide diversity of clinical symptoms experienced by individuals with coronavirus disease 2019 (COVID-19). Here, we report the metabolic changes associated with the peripheral immune response of 198 individuals with COVID-19 through an integrated analysis of plasma metabolite and…
Read More
A backpack-size kidney-dialysis device, conceived and being developed at the University of Washington Center for Dialysis Innovation (CDI), is one of six winners of a $650,000 prize in an international competition to create components and systems for artificial kidneys. The awards were announced today by KidneyX, a public-private partnership of the American Society of Nephrology and U.S. Department of Health and Human…
Read More
How variations in the DNA sequences in the human genome affect how cells’ function and, ultimately, how these variants influence human health and disease, are critical questions that will be addressed by a new research consortium. Scientists at the University of Washington School of Medicine will be part of this major, multi-institution effort. The National Institutes of Health has awarded $16 million to UW Medicine…
Read More
Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, announced the initiation of a Phase I/Ib clinical trial of IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F antigen, in healthy adults and older adults. Assuming favorable results from the IVX-121 Phase 1/1b clinical trial and favorable…
Read More
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Bill Arthur, Ph.D., as Vice President and Head of Research. Dr. Arthur joins Neoleukin after a decade at Seagen, where he served most recently as Senior Director & Head of Cancer Biology. During his time at Seagen, Dr. Arthur directed research efforts on therapeutic candidates,…
Read More
The key to overcoming addictions and psychiatric disorders lives deep inside the netherworld of our brains and the circuitry that causes us to feel good. Just like space, this region of the brain needs more exploration. The oldest and most known reward pathway is the mesolimbic dopamine system, which is composed of neurons projecting from the ventral tegmental area (VTA)…
Read More
For the past decade, scientists have performed genome-wide screens to identify important cancer genes – first with shRNA and in the past few years with CRISPR. However, we and others noticed that paralogs – duplicated genes – were underrepresented as hits in these screens. We wondered if this absence was due to redundancy between the two genes – if so, knocking out duplicated genes in tandem should produce an effect and reveal the function of the genes.
Read More
A-Alpha Bio will build lab space in downtown Seattle and beef up its machine learning team with $20 million in new venture funding for its operation to identify therapeutic proteins, the company announced Thursday. Seattle’s Madrona Venture Group, a tech-focused firm branching into the life sciences, led the Series A round. The funding propels the company from a grant-funded University…
Read More